Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine

Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine

International Journal of Cardiology

Saved in:

Bibliographic Details
Main Authors:	Almsherqi, Z.A., Deng, Y., McLachlan, C.S., Mossop, P.
Other Authors:	PHYSIOLOGY
Format:	Article
Published:	2011
Subjects:	Antiplatelet treatment Clopidogrel Percutaneous coronary intervention Ticlopidine
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/24965
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine
by: Almsherqi, Z.A., et al.
Published: (2016)

Non-bleeding side effects of clopidogrel: Have large multi-center clinical trials underestimated their incidence?
by: Almsherqi, Z.A., et al.
Published: (2011)

Non-bleeding side effects of clopidogrel: Have large multi-center clinical trials underestimated their incidence?
by: Almsherqi, Z.A., et al.
Published: (2016)

Switching from Ticagrelor to Clopidogrel in Asian Patients with ST-Elevated Myocardial Infarction – A Time Dependent Analysis Study
by: Koh L, et al.
Published: (2020)

Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention
by: Li, Y., et al.
Published: (2014)

A Scoping Review of The Percutaneous Coronary Intervention: Practice Transformation for the Operational Access
by: Sazzad, Faizus, et al.
Published: (2022)

Long-term follow-up after percutaneous coronary intervention in patients with systemic lupus erythematosus
by: Lee, C.-H., et al.
Published: (2016)

Angiographic no-reflow and six-month mortality in elderly (≥ 75 years old) Asian patients undergoing primary percutaneous coronary intervention: A single center experience from 1998 to 2007
by: Lee, C.-H., et al.
Published: (2011)

Comparison of the effect of rabeprazole and omeprazole on antiplatelet action of clopidogrel in patients receiving aspirin
by: Suksiri Siriswangvat
Published: (2012)

The impact of chronic kidney disease on long-term outcomes following semi-urgent and elective percutaneous coronary intervention
by: Soh, Rodney Yu-Hang, et al.
Published: (2021)

Diabetic patients with normal baseline renal function are at increased risk of developing contrast-induced nephropathy post-percutaneous coronary intervention
by: Chong, E., et al.
Published: (2016)

Time-dependent dynamic mobilization of circulating progenitor cells during percutaneous coronary intervention in diabetics
by: Lee, L.C., et al.
Published: (2011)

Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention
by: Bhatt, Deepak L., et al.
Published: (2022)

Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: A Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)
by: Bulluck, Heerajnarain, et al.
Published: (2022)

High dose Clopidogrel decreases mice liver mitochondrial respiration function in vitro
by: TAI YEE KIT, et al.
Published: (2016)

Impact of the COVID-19 Pandemic on Door-to-Balloon Time for Primary Percutaneous Coronary Intervention - Results From the Singapore Western STEMI Network -
by: Chew, Nicholas WS, et al.
Published: (2021)

Metabolic equivalent of exercise stress test explained by six-minute walk test in post coronary artery bypass graft and post percutaneous coronary intervention patients
by: Watesinee Khuangsirikul, et al.
Published: (2018)

The Asia-Pacific Evaluation of Cardiovascular Therapies (ASPECT) Collaboration - Improving the quality of cardiovascular care in the Asia Pacific Region
by: Reid, C.M., et al.
Published: (2016)

Characteristics and outcomes of young patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Retrospective analysis in a multiethnic Asian population
by: Tung, BWL, et al.
Published: (2021)

Microvascular obstruction after percutaneous coronary intervention
by: Lee, C.-H., et al.
Published: (2011)

Correlation of short form-36, energy expenditure and six-minute walk test in post coronary artery bypass graft and post percutaneous coronary intervention patients
by: Watesinee Kaewkhuntee, et al.
Published: (2018)

Percutaneous coronary intervention in asians- are there differences in clinical outcome?
by: Koh, A.S, et al.
Published: (2020)

Incidence and predictors of target lesion failure in a multiethnic Asian population receiving the SYNERGY coronary stent: A prospective all-comers registry
by: Ananthakrishna, Rajiv, et al.
Published: (2021)

ReoPro Observational Registry (RAPOR): Insights from the multicentre use of abciximab in Asia
by: Poh, K.K., et al.
Published: (2016)

Initial experience in the clinical use of everolimus-eluting bioresorbable vascular scaffold (BVS) in a single institution
by: Liang, M., et al.
Published: (2014)

Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: A prospective randomized study
by: Lee, C.-H., et al.
Published: (2014)

Improvement in coronary haemodynamics after percutaneous coronary intervention: Assessment using instantaneous wave-free ratio
by: Nijjer, S.S, et al.
Published: (2020)

The role of genetic polymorphism and other factors on clopidogrel resistance (Cr) in an asian population with coronary heart disease (chd)
by: Akkaif, MA, et al.
Published: (2021)

Clinical predictors of stent thrombosis in the "real world" drug-eluting stent era
by: Tin-Hay, E.L., et al.
Published: (2014)

Endothelial progenitor cell capture stent implantation in patients with ST-segment elevation acute myocardial infarction: One year follow-up
by: Lee, Y.-P., et al.
Published: (2014)

Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: A Singapore healthcare perspective
by: Chin, C.T., et al.
Published: (2014)

Evaluation of clopidogrel resistance [3]
by: Almsherqi, Z.A., et al.
Published: (2011)

Causes of delay in door-to-balloon time in south-east Asian patients undergoing primary percutaneous coronary intervention
by: Sim W.J., et al.
Published: (2019)

Purification and preliminary characterisation of praelongin phospholipases, antiplatelet agents from the snake venom of Acanthophis praelongus
by: Sim, K.L.
Published: (2014)

More on: Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: A randomized crossover trial [12]
by: Almsherqi, Z.A., et al.
Published: (2011)

More on: Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: A randomized crossover trial [12]
by: Almsherqi, Z.A., et al.
Published: (2016)

Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?
by: Gurbel, P.A., et al.
Published: (2016)

One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic
by: Phua, Kailun, et al.
Published: (2021)

Obstructive Sleep Apnea and Cardiovascular Events After Percutaneous Coronary Intervention
by: Lee, Chi-Hang, et al.
Published: (2016)

Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients
by: Muthiah, Mark D, et al.
Published: (2021)